Nationwide non-profit funding research and delivering cancer information and services
Federal SNAP reform has tightened eligibility and shifted costs to states, triggering a sharp drop in participation and putting pressure on food banks. Arizona records the largest decline, with state processes becoming more burdensome and delivery times longer as programs adjust. Projections warn of continued reductions without congressional action.
CMS has announced an end to the Part D subsidy at the end of 2026, signaling higher prescription costs for roughly 25 million beneficiaries. Insurers say pricing for 2027 will reflect the change, potentially widening premiums by up to $20 a month for some plans, while experts warn about broader affordability pressures and plan take-up shifts.
Sims, eight years after a melanoma diagnosis, is warning that tanning is surging again among young people online. Experts say tanning beds dramatically raise melanoma risk, with DNA mutations more likely in users. Reports show 100,000+ melanomas expected in 2026; influencers promote tanning, while dermatologists stress there is no safe tan.
Athletes and patients have urged Downing Street to appoint a national brain cancer lead and boost research funding. The Rare Cancers Bill is seen as a step forward but not enough, with calls for faster action in light of Commonwealth Games coverage and ongoing treatment campaigns.
Sydney Towle, 26, is transitioning to hospice care after years of cholangiocarcinoma treatment. Her brother’s TikTok updates have chronicled her journey, including a recent shift away from aggressive therapy toward comfort-focused care as she continues to seek innovative options.
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with previously treated or ineligible metastatic pancreatic cancer. Clinical trials have shown median survival extended to about 13.2 months versus roughly 6.7 months with chemotherapy. The drug will be available in the US with a roughly $39,800 monthly list price and expanded-access programmes have already treated thousands.
GLP-1 medications are being increasingly prescribed off-label to children aged 8–11 in the US, despite no FDA approval for under-12s. A NYU Langone study shows a dramatic rise in June 2026, while experts warn about long-term effects and the broader obesity crisis.
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Pope Leo XIV has undergone surgery at Rome’s Gemelli Hospital to remove a right‑lung nodule. Surgeons have confirmed lung adenocarcinoma and removed the lower lobe; doctors have said postoperative tests and X‑rays are normal and the pope has been discharged. The Vatican has not yet said whether additional treatment will be needed.